# TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

> **NCT00540449** · PHASE3 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 694 (actual)

## Conditions studied

- HIV Infections
- HIV-1
- Human Immunodeficiency Virus Type 1

## Interventions

- **DRUG:** TMC278
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT00540449
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-02
- **Final completion:** 2011-12
- **Target enrollment:** 694 (ACTUAL)
- **Last updated:** 2016-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540449, "TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00540449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*